Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers
about
Cytotoxic and targeted therapy for hereditary cancersNovel targets in the treatment of advanced gastric cancer: a perspective reviewSuccesses and Challenges of PARP Inhibitors in Cancer TherapyGenomic and Histopathological Tissue Biomarkers That Predict Radiotherapy Response in Localised Prostate CancerPredictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized MedicineMolecular Classification of Triple-Negative Breast CancerVeliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis.Impact of race and tumor subtype on second malignancy risk in women with breast cancer.Triple-negative breast cancer: treatment challenges and solutions.The EMSY threonine 207 phospho-site is required for EMSYdriven suppression of DNA damage repair.Precision medicine for metastatic breast cancer--limitations and solutions.Recently identified drug resistance biomarkers in ovarian cancer.Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.Catalog of genetic progression of human cancers: breast cancer.Unravelling the biology of SCLC: implications for therapy.BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.Triple Negative Breast Cancer at the University Hospital Mohammed VI – OujdaTherapeutic targeting and patient selection for cancers with homologous recombination defects.Mutational Signatures in Breast Cancer: The Problem at the DNA LevelNeoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.Histo-genomic stratification reveals the frequent amplification/overexpression of CCNE1 and BRD4 genes in non-BRCAness high grade ovarian carcinoma.Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugsThe c.*229C > T gene polymorphism in 3'UTR region of the topoisomerase IIβ binding protein 1 gene and LOH in BRCA1/2 regions and their effect on the risk and progression of human laryngeal carcinoma.Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative NeoplasmsBaseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.Targeted Proteomic Analyses of Histone H4 Acetylation Changes Associated with Homologous-Recombination-Deficient High-Grade Serous Ovarian Carcinomas.Tandem duplications contribute to not one but two distinct phenotypes.Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.Cyclin A2 regulates homologous recombination DNA repair and sensitivity to DNA damaging agents and poly(ADP-ribose) polymerase (PARP) inhibitors in human breast cancer cells.An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer.HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer.
P2860
Q26739366-95EBBCBC-000F-428C-82A5-1EF705F76CDFQ26765208-D4AAC44F-CA66-4FB3-959A-BDA71A2A863FQ26777131-A89EC861-1D4C-48D4-BA7B-2E1B65D4A8F0Q26778586-3965D2BC-A0DF-435C-97DB-9FB4F861DC8FQ28072204-E28641CA-8842-4072-AABC-544CFDC5C8EAQ28076661-2106F022-13BF-46BF-9090-D816A05661E9Q33429801-C69F09B2-F5A3-4B9F-B987-85506F5215DEQ33441772-9EDA6065-CB68-4F60-BFDC-958001EAF464Q35895214-95E83C83-146F-466C-B83A-A2BC14173821Q36166929-60432E57-AE41-4FD7-A586-9180EA019DD8Q36193912-28310C9E-FE79-4830-904A-DC3B2B13F61DQ36437353-D52E500F-6342-4E0B-AF44-6B3FF4B0E09EQ36940085-F5808EDD-014B-45BF-86B6-15CA81E19FE5Q38289381-8DC7E53D-C99F-49D0-8C89-A4BCCB221D67Q38551394-D1D10431-201E-4C20-82B4-35895A6D0B31Q38741073-06BC4F20-7A1F-40C1-8BC0-B180B8A58DBCQ38748208-725A8CC0-A11F-4688-8015-EFDC88A53A84Q38756892-55B91C12-A490-4293-847A-3540F0C05314Q38764251-EEE0BBFD-6652-4E7F-B82E-CD26D1DA90BCQ38769421-A75B5D69-2835-4616-9269-D3D574D43CCFQ38796030-96ED8796-2E6A-4017-9FB7-0A55957FC913Q38940118-A59DF7B4-18E7-41A8-8619-C399D8CED4F4Q39251572-E987F668-220C-45B0-83AC-A9847883BE33Q39345007-8BA77A0A-8A1E-4086-8922-8CD6B15AE5D6Q39375196-4BE0DAF1-48AA-4DF7-B3A8-53A1814AC6CFQ40640808-323C5D98-2672-4415-AEB8-CF62D5DC32B0Q41042069-DBE6C07F-5A6B-4F69-B66C-7A5C10898023Q41064551-F53D591D-D9E9-4E5E-AB39-E101C9020836Q41184434-162BE3A2-F468-47D0-BD0C-514E322608F1Q41217822-DF0C5732-BE82-4B65-BAC8-C10B668DFF74Q41470948-493E8C90-84D6-489E-94F3-DAA8E5365DDCQ41527706-73E07660-4E07-4F4B-82A1-924C1E9456DFQ42274807-2B3D3128-72D8-43FD-84E0-1DC662D77B5FQ42396208-A1510756-3D6F-4674-85B0-58C8E1142B62Q46270437-88FFF4D6-3286-4384-9D76-AAAFAED8DC38Q47101574-527435E0-8694-4B87-AFDF-F90F65FAA46FQ47140946-B4CAA286-CC57-488D-9AA4-863D3D4F2706Q48118236-45F51F20-8600-4A61-A87C-D2F1E1E2847DQ48134701-6C12E46C-7D1B-45C0-B320-8EFCD053896AQ49544395-FD1C0713-40F7-4397-8FDD-2DE01651AC07
P2860
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Genomic scars as biomarkers of ...... in breast and ovarian cancers
@ast
Genomic scars as biomarkers of ...... in breast and ovarian cancers
@en
Genomic scars as biomarkers of ...... in breast and ovarian cancers
@nl
type
label
Genomic scars as biomarkers of ...... in breast and ovarian cancers
@ast
Genomic scars as biomarkers of ...... in breast and ovarian cancers
@en
Genomic scars as biomarkers of ...... in breast and ovarian cancers
@nl
prefLabel
Genomic scars as biomarkers of ...... in breast and ovarian cancers
@ast
Genomic scars as biomarkers of ...... in breast and ovarian cancers
@en
Genomic scars as biomarkers of ...... in breast and ovarian cancers
@nl
P2860
P921
P3181
P356
P1476
Genomic scars as biomarkers of ...... in breast and ovarian cancers
@en
P2093
Andrew NJ Tutt
Johnathan A Watkins
P2860
P2888
P3181
P356
10.1186/BCR3670
P407
P5008
P577
2014-06-03T00:00:00Z
P5875
P6179
1044004169